Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021

SELL
$4.9 - $6.83 $2,616 - $3,647
-534 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$4.0 - $9.2 $2,136 - $4,912
534 New
534 $3,000
Q1 2020

May 14, 2020

SELL
$1.2 - $4.52 $110 - $415
-92 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$0.72 - $1.43 $554 - $1,101
-770 Reduced 89.33%
92 $0
Q3 2019

Nov 14, 2019

SELL
$1.43 - $3.81 $27,976 - $74,538
-19,564 Reduced 95.78%
862 $1,000
Q2 2019

Aug 14, 2019

SELL
$3.23 - $5.41 $896,244 - $1.5 Million
-277,475 Reduced 93.14%
20,426 $81,000
Q1 2019

May 15, 2019

BUY
$3.63 - $6.06 $654,129 - $1.09 Million
180,201 Added 153.1%
297,901 $1.28 Million
Q4 2018

Feb 14, 2019

BUY
$3.76 - $14.16 $406,613 - $1.53 Million
108,142 Added 1131.43%
117,700 $676,000
Q3 2018

Dec 21, 2021

BUY
$8.27 - $13.56 $78,986 - $129,511
9,551 Added 136442.86%
9,558 $130,000
Q3 2018

Nov 14, 2018

SELL
$8.27 - $13.56 $1.09 Million - $1.79 Million
-131,686 Reduced 99.99%
7 $0
Q2 2018

Apr 21, 2020

BUY
$10.42 - $13.74 $88,351 - $116,501
8,479 Added 6.88%
131,693 $1.56 Million
Q2 2018

Aug 14, 2018

SELL
$10.42 - $13.74 $2.22 Million - $2.92 Million
-212,672 Reduced 63.32%
123,214 $1.46 Million
Q1 2018

Oct 18, 2019

BUY
$7.1 - $11.56 $55,869 - $90,965
7,869 Added 2.4%
335,886 $3.77 Million
Q1 2018

May 15, 2018

BUY
$7.1 - $11.56 $1.09 Million - $1.77 Million
153,071 Added 87.5%
328,017 $3.68 Million
Q4 2017

Feb 14, 2018

SELL
$6.68 - $8.74 $775,467 - $1.01 Million
-116,088 Reduced 39.89%
174,946 $1.17 Million
Q3 2017

Nov 14, 2017

BUY
$4.93 - $8.93 $1.43 Million - $2.6 Million
291,034
291,034 $2.38 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $88.2M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.